---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-100350"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-09-16T12:00:14+00:00"
generated_at: "2026-09-16T12:05:32.367099+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Allarity wins Japanese patent for stenoparib DRP companion diagnostic; Japan protection runs to 2039

## Summary
- Japan Patent Office granted Japanese Patent No. 7917283 covering stenoparib-specific DRP companion diagnostic; Japan protection extends into 2039.
- Patent covers DRP methods predicting clinical benefit from stenoparib via tumor gene-expression profiles and patient-selection methods.
- Prior stenoparib DRP protection secured in US through April 2042, plus selected European jurisdictions and Australia; other filings pending.
- CEO Thomas Jensen cites Japan as key pharma market and home of Eisai, original stenoparib developer, supporting drug's developability.

## SEC filing metadata
- accession: 0001213900-26-100350
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-09-16T12:00:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026100350/0001213900-26-100350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026100350/ea0305570-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-100350
- JSON: https://secwatch.observer/filing/0001213900-26-100350.json
- Plain text: https://secwatch.observer/filing/0001213900-26-100350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.